YM155, a novel small molecule survivin suppressant, exhibits curative antitumor activities in experimental human malignant lymphoma models in vivo

被引：1

作者：

Kita, A.

Nakahara, T.

Yamanaka, K.

Koutoku, H.

Takeuchi, M.

Kinoyama, I.

Matsuhisa, A.

Sasamata, M.

机构：

[1] Astellas Pharma Inc, Pharmacol Res Labs, Tsukuba, Ibaraki, Japan

[2] Astellas Pharma Inc, Mol Med Res Labs, Tsukuba, Ibaraki, Japan

[3] Astellas Pharma Inc, Chem Res Labs, Tsukuba, Ibaraki, Japan

来源：

EJC SUPPLEMENTS | 2006年 / 4卷 / 12期

关键词：

D O I：

10.1016/S1359-6349(06)70382-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

377

引用

页码：116 / 116

页数：1

共 46 条

[31] YM155, a novel survivin suppressant, demonstrates anti-tumor activity in patients with advanced solid tumors and non-Hodgkin's lymphoma [J].

Tolcher, AW ;

Antonia, S ;

Lewis, LD ;

Mita, A ;

Mahany, JJ ;

Reddy, NJ ;

Till, E ;

Buell, D ;

Keating, AT .

ANNALS OF ONCOLOGY, 2006, 17 :23-23

[32] Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model [J].

Murakami, Yoshihiro ;

Matsuya, Takahiro ;

Kita, Aya ;

Yamanaka, Kentaro ;

Noda, Akihiro ;

Mitsuoka, Keisuke ;

Nakahara, Takahito ;

Miyoshi, Sosuke ;

Nishimura, Shintaro .

NUCLEAR MEDICINE AND BIOLOGY, 2013, 40 (02) :221-226

[33] YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model [J].

Nakahara, Takahito ;

Yamanaka, Kentaro ;

Hatakeyama, Shinji ;

Kita, Aya ;

Takeuchi, Masahiro ;

Kinoyama, Isao ;

Matsuhisa, Akira ;

Nakano, Kenji ;

Shishido, Takao ;

Koutoku, Hiroshi ;

Sasamata, Masao .

ANTI-CANCER DRUGS, 2011, 22 (05) :454-462

[34] A phase II, monotherapy study of YM155, a novel survivin suppressant, in previously treated advanced stage non-small cell lung cancer (NSCLC) [J].

Giaccone, Giuseppe ;

Zatloukal, Petr ;

Roubec, Jaromir ;

Musil, Jaromir ;

Kuta, Milan ;

van Klaveren, R. J. ;

Chaudhary, Subhash ;

Gunther, Adrie ;

Shamsili, Setareh ;

Kazei, Dmitri ;

Verbeeck, Frank .

MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) :3597S-3597S

[35] Effect of YM155, a potent survivin suppressant, on the antitumor effect of rituximab in diffuse large B-cell lymphoma (DLBCL) xenograft models: FLT-/FDG-PET imaging studies. [J].

Mitsuoka, K. ;

Miyoshi, S. ;

Kita, A. ;

Yamanaka, K. ;

Nakata, M. ;

Murakami, Y. ;

Noda, A. ;

Jitsuoka, M. ;

Fushiki, H. ;

Nishimura, S. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[36] A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer [J].

Tolcher, A. W. ;

Quinn, D. I. ;

Ferrari, A. ;

Ahmann, F. ;

Giaccone, G. ;

Drake, T. ;

Keating, A. ;

de Bono, J. S. .

ANNALS OF ONCOLOGY, 2012, 23 (04) :968-U9

[37] Population pharmacokinetic modeling of Sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma [J].

Yumiko Aoyama ;

Atsunori Kaibara ;

Akitsugu Takada ;

Tetsuya Nishimura ;

Masataka Katashima ;

Taiji Sawamoto .

Investigational New Drugs, 2013, 31 :443-451

[38] Population pharmacokinetic modeling of Sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma [J].

Aoyama, Yumiko ;

Kaibara, Atsunori ;

Takada, Akitsugu ;

Nishimura, Tetsuya ;

Katashima, Masataka ;

Sawamoto, Taiji .

INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) :443-451

[39] Utility of P-Glycoprotein and Organic Cation Transporter 1 Double-Transfected LLC-PK1 Cells for Studying the Interaction of YM155 Monobromide, Novel Small-Molecule Survivin Suppressant, with P-Glycoprotein [J].

Iwai, Megumi ;

Minematsu, Tsuyoshi ;

Li, Qun ;

Iwatsubo, Takafumi ;

Usui, Takashi .

DRUG METABOLISM AND DISPOSITION, 2011, 39 (12) :2314-2320

[40] DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo [J].

Meng-yuan Li ;

Yong-cong Lv ;

Lin-jiang Tong ;

Ting Peng ;

Rong Qu ;

Tao Zhang ;

Yi-ming Sun ;

Yi Chen ;

Li-xin Wei ;

Mei-yu Geng ;

Wen-hu Duan ;

Hua Xie ;

Jian Ding .

Acta Pharmacologica Sinica, 2016, 37 :398-407

← 1 2 3 4 5 →